In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kratom Industry GMPs Target Swaying FDA By Exceeding Agency Standards

This article is powered by The Rose Sheet

Executive Summary

“We want to show that the kratom industry is maturing, that people want to do the right thing,” says AKA Chairman Dave Herman. The standards go “well beyond” FDA's minimum GMP requirements for dietary supplements, AKA says.


Related Content

Kratom Industry Offers Own Standards As Another Firm Warned About FDA Rules
Warnings On Kratom Opioid Withdrawal Claims Mark Tip Of FDA Concerns
Kratom Group Contests FDA's Opioid Finding, Requests Joint Meeting With NIDA
Salmonella In Kratom, Like Use Of The Herb, Exceeds FDA Expectations
Kratom Experts Seek NIDA As Ally To Show Herb's Safety And Benefits
FDA Turns Kratom's Future In US Dietary Supplement Market Into History
DEA Proposal To Schedule Kratom Stirs Wave Of Opposition





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts